Back to Search
Start Over
Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial
- Source :
- Circulation. Cardiovascular interventions. 14(11)
- Publication Year :
- 2021
-
Abstract
- Background: Early bleeding after percutaneous coronary intervention is associated with increased risk of death and myocardial infarction; however, the association between bleeding and subsequent major adverse cardiac and cerebrovascular events (MACCE) remains unclear in patients with atrial fibrillation and stable coronary artery disease. We thus aimed to investigate this association. Methods: The AFIRE trial (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) was a multicenter, open-label trial conducted in Japan. This post hoc analysis included 2215 patients with atrial fibrillation and stable coronary artery disease treated with rivaroxaban or rivaroxaban plus an antiplatelet agent. MACCE was defined as a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause. The association of bleeding with subsequent MACCE risk was investigated using time-adjusted Cox multivariate analysis after adjusting for baseline characteristics and time from bleeding. Bleeding events were classified according to the International Society on Thrombosis and Haemostasis criteria. Results: Among the 2215 patients, 386 (17.4%) had bleeding during follow-up, of whom 63 (16.3%) also experienced MACCE; MACCE incidence was higher in patients with bleeding than in those without (8.38% versus 4.20% per patient-year; hazard ratio, 2.01 [95% CI, 1.49–2.70]; P Conclusions: In patients with atrial fibrillation and stable coronary artery disease, major bleeding was strongly associated with subsequent MACCE. Thus, it is important to prevent major bleeding to avoid cardiovascular events and death. Registration: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000016612. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02642419. Graphic Abstract: A graphic abstract is available for this article.
- Subjects :
- medicine.medical_specialty
medicine.medical_treatment
Hemorrhage
Coronary Artery Disease
Coronary artery disease
Percutaneous Coronary Intervention
Rivaroxaban
Bleeding time
Risk Factors
Internal medicine
Atrial Fibrillation
medicine
Humans
Multicenter Studies as Topic
Myocardial infarction
Randomized Controlled Trials as Topic
medicine.diagnostic_test
business.industry
Incidence (epidemiology)
Percutaneous coronary intervention
Atrial fibrillation
medicine.disease
Stroke
Increased risk
Treatment Outcome
Cardiology
Cardiology and Cardiovascular Medicine
business
Platelet Aggregation Inhibitors
Subjects
Details
- ISSN :
- 19417632
- Volume :
- 14
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Circulation. Cardiovascular interventions
- Accession number :
- edsair.doi.dedup.....8451c2ad26e543f0a378f7f83f143d97